Whole population(N = 56
patients, 395
samples, 194 courses)

DEM+ (N = 179 samples, 26 courses)

DEM- (N = 216
samples, 168 courses)

Age<18 y>18 y

37 (66.1%)19
(33.9%)

133 (74.3%)46 (25 .7%)

153 (70.8%)63
(29.2%)

Weight (kg)

30 [10-90]

30 [10-90]

30 [10-90]

Gender (M/F)

34/22 (1.54)

123/56 (2,19)

123/93 (1.32)

Cancer typeAcute lymphoblastic leukemia Non-hodgkin’s lymphomaLymphoblastic lymphoma BLymphoblastic lymphoma TCutaneous lymphomaOsteosarcoma

31 (55.3%)21
(37.5%)1 (0.17%)1
(0.17%)1 (0.17%)1
(0.17%)

109 (60.8%)52 (29%)10
(0.55%)2 (0.11%)3
(0.17%)3(0.17%)

107 (49.5%)77
(35.6%)17
(0.78%)6 (0.27%)1
(0.04%)8 (0.37%)

MTX dose (g)/course

5 [1.2-17]

5 [1.2-17]

5 [1.2-17]

MTX time infusion 3-h infusion 24-h infusion

230165

9188

13977

Renal impairement

7 patients (30 C )
MTX

6 patients (24 C )
MTX

4 patients (6 C )
MTX

Number of courses

2 [1-9]

3 [1-9]

2 [1-9]

MTX concentration < toxic levelat 24hat 36hat 48hat 72h at 96hat 120h>120 h

146/395 (36.9%)1/41 (0.02%)1/17 (0.5%)42/158 (2.6%)60/96 (6.2%)20/37 (5.4%)8/14 (5.7%)14/32 (4.3%)

102/146(69.8%)00060/102 (58.8%)20 /102 (19.6%)8/102 (7.8%)14/102 (13.8%)

44/146(30.2%)1/44 (2.3%1/44 (2.3%)42/44 (95.4%)----

Leucovorin rescue at 24 hat 36 hat 48 hat 72h at 96at 120 h>120 h

841150107313

34000117313

5011490000

Associated
chemotherapy :EndoxanCytarabinVincristinPurinetholDoxorubicinOncovinImatinibL asparaginase

2932561021735515

1011225171738

19213451101827

Univariate analysis

MultivariateAnalysis

Binary variable

p- value

Odds ratio(95% confidence interval)

p- value

Age (<18 y/ >18 y)

0.79

-

-

Gender (M/F)

0.016

2.11 [1.31- 3.39]

0.002

MTX time infusion*

0.0069

1.30 [0.84- 2.01]

0.23

Renal impairement (Y/N)

0.0003

5.97 [2.01- 17.72]

0.001

Number of courses (1 or >1)

0.005

0.83 [0.51- 1.33]

0.44

Continuous variable

p- value

Β-coefficient (95% confidence interval)

p- value

MTX dose/course

0.0002

0.91 [0.83- 0.99]

0.03

Weight

0.001

0.99 [0.98- 1.00]

0.47